Cargando…

Postmastectomy locoregional recurrence and recurrence-free survival in breast cancer patients

BACKGROUND: One essential outcome after breast cancer treatment is recurrence of the disease. Treatment decision is based on assessment of prognostic factors of breast cancer recurrence. This study was to investigate the prognostic factors for postmastectomy locoregional recurrence (LRR) and surviva...

Descripción completa

Detalles Bibliográficos
Autores principales: Kheradmand, Ali Arab, Ranjbarnovin, Neda, Khazaeipour, Zahra
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868847/
https://www.ncbi.nlm.nih.gov/pubmed/20398406
http://dx.doi.org/10.1186/1477-7819-8-30
_version_ 1782181074206457856
author Kheradmand, Ali Arab
Ranjbarnovin, Neda
Khazaeipour, Zahra
author_facet Kheradmand, Ali Arab
Ranjbarnovin, Neda
Khazaeipour, Zahra
author_sort Kheradmand, Ali Arab
collection PubMed
description BACKGROUND: One essential outcome after breast cancer treatment is recurrence of the disease. Treatment decision is based on assessment of prognostic factors of breast cancer recurrence. This study was to investigate the prognostic factors for postmastectomy locoregional recurrence (LRR) and survival in those patients. METHODS: 114 patients undergoing mastectomy and adjuvant radiotherapy in Cancer Institute of Tehran University of Medical Sciences were retrospectively reviewed between 1996 and 2008. All cases were followed up after initial treatment of patients with breast cancer via regular visit (annually) for discovering the LRR. Cumulative recurrence free survival (RFS) was determined using the Kaplan-Meier method, with univariate comparisons between groups through the log-rank test. The Cox proportional hazards model was used for multivariate analysis. RESULT: The median follow up time was 84 months (range 2-140). Twenty-three (20.2%) patients developed LRR. Cumulative RFS rate at 2.5 years and 5 years were 86% (95%CI, 81-91) and 82.5% (95%CI, 77-87) respectively. Mean RFS was 116.50 ± 4.43 months (range, 107.82 - 125.12 months, 95%CI). At univariate and multivariate analysis, factors had not any influence on the LRR. CONCLUSION: Despite use of adjuvant therapies during the study, we found a LRR rate after mastectomy of 20.2%. Therefore, for patients with LRR without evidence of distant disease, aggressive multimodality therapy is warranted.
format Text
id pubmed-2868847
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28688472010-05-13 Postmastectomy locoregional recurrence and recurrence-free survival in breast cancer patients Kheradmand, Ali Arab Ranjbarnovin, Neda Khazaeipour, Zahra World J Surg Oncol Research BACKGROUND: One essential outcome after breast cancer treatment is recurrence of the disease. Treatment decision is based on assessment of prognostic factors of breast cancer recurrence. This study was to investigate the prognostic factors for postmastectomy locoregional recurrence (LRR) and survival in those patients. METHODS: 114 patients undergoing mastectomy and adjuvant radiotherapy in Cancer Institute of Tehran University of Medical Sciences were retrospectively reviewed between 1996 and 2008. All cases were followed up after initial treatment of patients with breast cancer via regular visit (annually) for discovering the LRR. Cumulative recurrence free survival (RFS) was determined using the Kaplan-Meier method, with univariate comparisons between groups through the log-rank test. The Cox proportional hazards model was used for multivariate analysis. RESULT: The median follow up time was 84 months (range 2-140). Twenty-three (20.2%) patients developed LRR. Cumulative RFS rate at 2.5 years and 5 years were 86% (95%CI, 81-91) and 82.5% (95%CI, 77-87) respectively. Mean RFS was 116.50 ± 4.43 months (range, 107.82 - 125.12 months, 95%CI). At univariate and multivariate analysis, factors had not any influence on the LRR. CONCLUSION: Despite use of adjuvant therapies during the study, we found a LRR rate after mastectomy of 20.2%. Therefore, for patients with LRR without evidence of distant disease, aggressive multimodality therapy is warranted. BioMed Central 2010-04-17 /pmc/articles/PMC2868847/ /pubmed/20398406 http://dx.doi.org/10.1186/1477-7819-8-30 Text en Copyright ©2010 Kheradmand et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Kheradmand, Ali Arab
Ranjbarnovin, Neda
Khazaeipour, Zahra
Postmastectomy locoregional recurrence and recurrence-free survival in breast cancer patients
title Postmastectomy locoregional recurrence and recurrence-free survival in breast cancer patients
title_full Postmastectomy locoregional recurrence and recurrence-free survival in breast cancer patients
title_fullStr Postmastectomy locoregional recurrence and recurrence-free survival in breast cancer patients
title_full_unstemmed Postmastectomy locoregional recurrence and recurrence-free survival in breast cancer patients
title_short Postmastectomy locoregional recurrence and recurrence-free survival in breast cancer patients
title_sort postmastectomy locoregional recurrence and recurrence-free survival in breast cancer patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868847/
https://www.ncbi.nlm.nih.gov/pubmed/20398406
http://dx.doi.org/10.1186/1477-7819-8-30
work_keys_str_mv AT kheradmandaliarab postmastectomylocoregionalrecurrenceandrecurrencefreesurvivalinbreastcancerpatients
AT ranjbarnovinneda postmastectomylocoregionalrecurrenceandrecurrencefreesurvivalinbreastcancerpatients
AT khazaeipourzahra postmastectomylocoregionalrecurrenceandrecurrencefreesurvivalinbreastcancerpatients